Clinical development of cancer vaccines - PubMed
a day ago
- #immunotherapy
- #cancer vaccines
- #clinical trials
- Current immune checkpoint inhibitor therapies have limitations, necessitating improved strategies to expand tumor-reactive T cell repertoires safely and efficiently.
- Cancer vaccines show potential but have not yet matched the success of infectious disease vaccines in clinical settings.
- Recent phase 1 and 2 clinical trials have provided encouraging results, leading to large-scale cancer vaccine trials.
- Key strategies for optimizing cancer vaccines include better proxies for efficacy estimation, high-quality antigen selection (especially neoantigens), and modular vaccine platforms with innate immunostimulatory capabilities.
- Focusing on early-stage cancer, such as (neo)adjuvant therapies, is crucial for future cancer vaccine development.
- The authors disclose various advisory roles, equity holdings, and research funding from multiple biotech and pharmaceutical companies, though these relationships did not impact the study.